CDXS Stock Analysis: Buy, Sell, or Hold?
CDXS - Codexis, Inc.
$2.47
0.08 (3.35%)
▲
5d:
+9.78%
30d:
-8.18%
90d:
+41.95%
HOLD
MODERATE Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When CDXS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CDXS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CDXS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: CDXS is currently trading at $2.47, which is considered fair relative to its 30-day fair value range of $2.34 to $2.66. From a valuation perspective, the stock is trading at a discount (Forward PE: -6.7) compared to its historical average (16.6). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CDXS is in a strong uptrend. Immediate support is located at $2.17, while resistance sits at $2.64. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: CDXS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.58 (+166.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CDXS is in a strong uptrend. Immediate support is located at $2.17, while resistance sits at $2.64. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: CDXS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $6.58 (+166.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.34 -
$2.66
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
59.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 166.5% below Wall St target ($6.58)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$2.34 -
$2.66
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$2.18
Resistance Level
$2.64
Current Trend
Strong Uptrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.68
Wall Street Target
$6.58
(+166.5%)
Revenue Growth (YoY)
102.1%
Profit Margin
-41.0%
PE vs Historical
-6.7 vs 16.6
CHEAP
Share & Embed Analysis
Last updated: July 04, 2026 5:36 AM ET
Data refreshes hourly during market hours. Next update: 6:36 AM
Data refreshes hourly during market hours. Next update: 6:36 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CDXS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Stefan Lutz
SELL
5862 shares
2026-02-24
Alison Moore
SELL
3826 shares
2026-02-06
Georgia Erbez
SELL
3826 shares
2026-02-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
